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Abstract: Microalbuminuria is considered to
be an early indicator of diabetic nephropathy.
We have previously reported the
establishment of A-HAlb/98 hybridoma
secreting monoclonal antibody that specifically
recognizes human serum albumin (HSA). In
this report, an in-house enzyme-linked
immunosorbent assay (ELISA) was developed
using this antibody for the measurement of
urinary albumin (UA) and UA was examined in
24 different samples. A-HAlb/98 was used as
the capture antibody by immobilizing onto
microtitre plates in ELISA format. HSAspecific polyclonal rabbit immunoglobulin was
labelled with biotin and then used as the
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tracer antibody. The dynamic assay range of
ELISA for albumin was established to be 101000 ng/ml, and the albumin levels
determined by ELISA were well correlated
(r = 0.8831) with those obtained by the
liquid-phase immunoprecipitation method
(The Orion Diagnostica TURBOX® U-albumin
assay). The ability of this in-house ELISA to
quantitate UA in nanogram ranges makes it a
favourable candidate for utilization in
diagnostic applications as well as in research
studies.
Key Words: Human albumin, Monoclonal
antibody, Polyclonal antibody, ELISA

Introduction

Materials and Methods

In healthy humans albumin is excreted in small
amounts in the urine. However, in diabetic nephropathy
the urinary albumin levels are increased (1). It was also
reported that faecal albumin levels were increased in
patients with colorectal cancers (2). The composition of
saliva is altered in patients with diabetes, with increased
secretion of calcium and immunoglobulin (3). It has been
suggested that this might result from an increase in
microvascular permeability (3). Although salivary acinar
cells do not secrete albumin, it might enter the saliva (4)
following leakage from surrounding blood vessels
because the molecular weight of albumin is lower than
that of immunoglobulin. Albumin concentrations in the
cerebrospinal fluid (CSF) were also reported to be at low
levels ranging from 100 to 800 µg per ml (5) and the IgG
levels, IgG/albumin ratios and IgG indexes were
significantly increased in the CSF of multiple sclerosis
(MS) patients compared to those of non-MS controls (6).

Human albumin. Human serum albumin (HSA,
approx. 99% (agarose electrophoresis), essentially fatty
acid free (approx. 0.005%), essentially globulin free,
lyophilized powder) was purchased from Sigma Chemical
Co. St. Louis, MO, USA.

In order to measure albumin as a predictive marker in
some situations such as that mentioned above, a highly
sensitive and specific method for determining low
concentrations of albumin is needed. The aim of the
present study was to develop an ELISA for quantifying
human albumin in urine samples.

Monoclonal antibody. A-HAlb/98 hybridoma cells
were used as the source of IgG1 monoclonal antibodies
specific for HSA (7). Monoclonal antibodies were purified
from ascites using a protein G affinity column (8). Protein
contents were measured with the Bradford method (9)
using bovine serum albumin (BSA, Sigma, St. Louis, MO,
USA) as the standard.
Polyclonal antibody. An albino rabbit was immunized
with 200 µl of antigen (200 µg of HSA) in 200 µl of
complete Freund’s adjuvant followed by a second injection
in 200 µl of incomplete Freund’s adjuvant at 30-day
intervals. Two booster injections, with antigen only, were
performed at 20-day intervals. In order to obtain serum
samples, the rabbit was bled from the central auricle
artery 10 days after the last injection. All subcutaneous or
intradermal injections and blood collections were
performed after anaesthetizing the rabbit with an
intramuscular injection of ketamin/xylazine cocktail. AntiHSA polyclonal antibody containing rabbit IgG was
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purified from the serum using a protein A affinity column
(8). The biotinylation of IgG was performed as described
elsewhere (10). A working concentration of biotinylated
rabbit IgG was prepared by diluting to 1:10,000 in PBS
containing 5% foetal calf serum (FCS, Seromed,
Biochrom KG Leonarenstr. 2-6 D-12247 Berlin,
Germany).
Urine samples. Twenty-four different urine samples
were collected and frozen at – 74 °C until the day of
study.
Enzyme-linked immunoabsorbent assay (ELISA).
High binding capacity ELISA plates (Costar, No: 3590,
Corning Incorporated, Corning, NY 14831, USA) were
coated with 100 µl of ascite-purified A-HAlb/98 at 1
µg/ml in 50 mM carbonate-bicarbonate buffer pH 9.6 by
incubating at 4 °C overnight. After several washings with
distilled water, the wells were blocked with 300 µl of PBS
containing 1% BSA by incubating at 4 °C overnight
followed by washing three times with PBS containing
0.05% Tween 20 (PBS-T). To each well was added 100
µl of 1/100 diluted samples or standards, followed by
incubation at 37 °C for 1 h. After incubation, the plates
were washed three times with PBS-T and then incubated
with 100 µl of biotinylated rabbit anti-HSA polyclonal IgG
at 37 °C for 1 h. After incubation, the plates were
washed three times with PBS-T and then incubated with
100 µl of streptavidine-peroxidase (Sigma Chemical Co.
St. Louis, MO, USA) at 37 °C for 30 min. After washing,
the
reaction
was
revealed
with
3,3’,5,5’
tetramethylbenzidine (TMB) solution, formulated in our
laboratory, for 30 min at room temperature. After
stopping the reaction with 50 µl of 2M H2SO4, the plates
were read with an ELISA reader (LP400, Diagnostics
Pasteur, France) at 450 nm with or without the reference
against 620 nm.
Liquid-phase immunoprecipitation assay. The
Orion Diagnostica TURBOX® U-albumin assay (Orion
Corporation Orion Diagnostica, Espoo, Finland), which is
a
commercially
available
liquid-phase
immunoprecipitation assay with nephelometric end-point
detection, was used to measure albumin levels in 24
different urine samples for comparison. The kit was used
according to the manufacturer’s instructions.
Statistical analysis. Comparison of the data between
the various methods was performed with correlation
analysis. P < 0.05 was considered significant. Intra- and
inter-assay coefficients of variation (CV) were measured
according to the following formula:
2

CV = S • 100% =
X

Σ (X - X)2 • 100%
N-1
X

where
S = standard deviation of optical density (OD)
readings,
–
X = mean of OD readings,
X = individual OD readings,
N = number of readings (wells)

Results
The in-house human albumin ELISA demonstrated a
sensitivity level of less than 10 ng/ml (Figure 1). The
dynamic analytical measuring range was between 10 and
1000 ng per ml. When four calibration points (0, 10,
100, and 1000 ng/ml) were plotted, a significant
correlation (p = 0.027, r = 0.972) between albumin
levels and OD450 nm values was observed (Figure 1).
Albumin concentrations higher than 1000 ng/ml
produced overflow values at OD450 nm.
The quality control of the in-house albumin ELISA was
performed by analysing its intra- and inter-assay CV.
When human albumin at various concentrations was
tested, the intra- and inter-assay CV values were 1.87.4% and 6.2-9.3% respectively (Table).
Albumin levels of 24 different urine samples were
measured with both the in-house ELISA and a commercial
microalbuminuria kit, TURBOX®, which is designed to
quantify albumin levels between 5 and 160 mg/l. There
was a significant correlation (p < 0.0001, r = 0.883)
between the albumin levels measured with two different
assay types (Figure 2).

Discussion
Quantification of albumin in microgram levels has
been studied in various body fluids as well as tissues
either for diagnostic or investigational purposes (2,3,6).
These concerns fall in a very wide clinical range and the
investigational spectra have to rely on a simple, sensitive
and cheap measuring method, especially in the case of
countries with limited health budgets.
The detection of microalbuminuria (mAlbU) has been
reported to indicate a high probability of damage to the
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Figure 1.

Enzyme-linked immunosorbent assay of human albumin.
A-HAlb/98 mAb-immobilized microtitre wells were incubated with varying amounts of human albumin as indicated (see text for details). Binding was detected with biotinylated rabbit anti-human albumin second antibody/streptavidine-HRP conjugate and TMB substrate. A prominent correlation (r = 0.9721, p = 0.027) was observed between
the albumin concentration and the optical density. Results
are the mean of quadruplicate observations.

Table.

Intra- and inter-assay coefficients of variation (CV) of
albumin ELISA.

Standard
(ng/ml)

Intra-assay CV
(%) (n = 5)

Inter-assay CV
(%) (n = 4)

1000
100
10

1.8
2.1
7.4

8.6
6.2
9.3

glomerular filtration capacity of the kidneys and is of
great screening and/or diagnostic interest (11,12).
Diabetes mellitus is the leading cause of end-stage renal
diseases and routine screenings for mAlbU is a wellestablished recommendation for type I and type II
diabetes in recent guidelines (11). With regard to the
time process of diabetes, it is obvious that patients have
to be followed-up for many years and albuminuria
develops within the first few years after the onset of
diabetes (12).
The important role of screening and quantifying
mAlbU as a risk factor for cardiovascular disease and
vascular dysfunction is also emphasized in recent reports
(13-18) and mAlbU has been established as a risk factor
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Comparison of the in-house ELISA and TURBOX® for
human albumin levels in urine samples. Twenty-four urine
samples were measured for their albumin contents with the
in-house ELISA and a commercial kit, TURBOX®, which is
a liquid–phase immunoprecipitation assay with nephelometric end-point detection. For the in-house ELISA, urine
samples were first diluted to 1/100 and then OD values
were plotted against the standard curve to find out albumin
contents. The results were multiplied by the dilution factor
and then converted to µg/ml. There was a significant correlation (r = 0.8831, p < 0.0001) between the two different types of assay.

for developing left ventricular hypertrophy (19). Beyond
these major clinical concerns its role as a scoring system
in critically ill patients admitted to intensive care units
with a wide range of diagnoses (20) and as a prognostic
factor in patients with acute respiratory or multi-organ
failure has been proposed (21). The quantifying of mAlbU
has also been studied as an objective marker for the
outcome effects of various therapies (22-26) in different
patient populations. Its role as a predictor of preeclampsia in pregnant hypertensive women (27) or of
gestational age at delivery (28) has also been
documented. Levels of mAlbU have also been related to
the tumour burden in non-Hodgkin’s lymphoma patients
(29) and in patients with lung cancer (30).
Microalbuminuria is reported to be a marker for nephron
development in various age groups (31).
Although timed sampling (12-24 h collection of urine)
is recommended as the sampling method (11), random
urine samples have been also documented as a reliable
sampling method for the quantification of mAlbU (32). In
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the determination of the level of mAlbU, several methods
have been employed in clinical and intervention studies
and it has been shown that there could be discordance
among various methods (33). Therefore, the method
used for quantification should be simple and reliable and
should have a high sensitivity in measuring the
microalbumin level (11), especially in a range appropriate
to that demarcating normal from microalbuminuric
patients. Because of the possible therapeutic decisions
with regard to treatment or follow-up, it is essential that
accurate and reproducible methodologies with high
sensitivity be employed. Otherwise misclassifications
could lead to incorrect decisions.
The results of our mAb-based in-house ELISA display
a quite sensitive level for the measurement of
microalbuminuria. When the human serum albumin of
known concentrations was used for the validation of our
in-house assay, we obtained a quite favourable and
significant correlation (r = 0.972, p = 0.027) for the
tested calibration points. The in-house assay displayed
overflow values at albumin concentrations greater than
1000 ng/ml, corresponding to the upper detection limit.
In respect to the lower analytical limit, 10 ng/ml could be
concluded to be the sensitivity of our in-house ELISA. We
obtained a dynamic analytical measuring range of 10 to
1000 ng/ml, a range appropriate to that demarcating
normal from microalbuminuric patients. For the quality
control of the mAb based in-house assay, three different
concentrations of standard human albumin were tested.
Data obtained on intra- and inter-assay CV precision were
analysed. Even at the lowest concentration of albumin
(10 ng/ml) we obtained intra- and inter-assay CV of less
than 10%. For all of the tested concentrations of
standard human albumin the intra-and inter-assay CV
showed dispersion indices with values of less than 10%,
corresponding to quite satisfactor levels.

The in-house mAb based ELISA was compared with a
commercially
available
kit,
the
TURBOX®
microalbuminuria assay, which is a liquid-phase
immunoprecipitation method with nephelometric endpoint detection. The TURBOX® microalbuminuria assay is
a commonly used system for both screening and
diagnostic purposes in routine laboratories. All of the 24
void samples were tested with both the in-house ELISA
and the TURBOX®. The results of the albumin levels
measured with our in-house ELISA and the TURBOX®
displayed a significant correlation (r = 0.8831, p <
0.0001). However, the in-house ELISA was detected to
be sensitive beyond the minimum measuring level given
for the TURBOX®. It can be concluded that in practical
terms the mAb-based in-house ELISA appears to be more
suitable and sensitive for mAlbU quantification than the
commercially available liquid-phase immunoprecipitation
assay.
The in-house ELISA seemed to be more advantageous
because of its reliability and low cost compared to the
commercially available kit. In addition, it may be
promising for routine or investigational analysis of
albumin at low concentrations in various body fluids. In
summary, the present results suggest that the in-house
mAb-based ELISA is a reliable and precise method for
determining microalbuminuria.
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